Our results indicate that targeted inhibition of HMGB1 expression in AML can suppress cell proliferation, induce cell apoptosis, and overcome differentiation blockade, implicating HMGB1 as a promising therapeutic target in AML. Here, HMGB1 is linked to acute myeloid leukemia.